The use of US health insurance data for surveillance of rare disorders: hereditary hemorrhagic telangiectasia
Purpose: To assess the utility of US health insurance data for surveillance of hereditary hemorrhagic telangiectasia, an autosomal-dominant blood vasculature disorder with an estimated prevalence of 1.5–2.0 per 10,000 persons worldwide. Methods: We used 2005–2010 MarketScan Research Databases to ide...
Gespeichert in:
| Veröffentlicht in: | Genetics in medicine 2014-01, Vol.16 (1), p.33-39 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 39 |
|---|---|
| container_issue | 1 |
| container_start_page | 33 |
| container_title | Genetics in medicine |
| container_volume | 16 |
| creator | Grosse, Scott D. Boulet, Sheree L. Grant, Althea M. Hulihan, Mary M. Faughnan, Marie E. |
| description | Purpose:
To assess the utility of US health insurance data for surveillance of hereditary hemorrhagic telangiectasia, an autosomal-dominant blood vasculature disorder with an estimated prevalence of 1.5–2.0 per 10,000 persons worldwide.
Methods:
We used 2005–2010 MarketScan Research Databases to identify individuals with employer-sponsored health insurance and International Classification of Disease, 9th Revision, Clinical Modification codes of 448.0 present in either one inpatient claim or two outpatient claims 30 days apart to define hereditary hemorrhagic telangiectasia. We examined frequencies of International Classification of Disease, 9th Revision, Clinical Modification codes for conditions that are complications of hereditary hemorrhagic telangiectasia among individuals with hereditary hemorrhagic telangiectasia and the general population to identify combinations of codes associated with hereditary hemorrhagic telangiectasia.
Results:
Excluding observations from one state, the average prevalence of hereditary hemorrhagic telangiectasia was 0.3 per 10,000 persons. The reported prevalence rose with age from ~0.1 per 10,000 at ages |
| doi_str_mv | 10.1038/gim.2013.66 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4453870</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1639473724</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-b51f3a63ade486a6b0cb6ec709753acce28e757a84e6ec02dda6211352967efb3</originalsourceid><addsrcrecordid>eNqFkc9r3TAMx83YWNu3nXofPg7avNlxYic9DEbpfkBhh7VnozhK4pLErZwU-t_Xb68rHQx2ktD3IyHpy9ixFFspVPWp99M2F1JttX7FDmWpRCaU1q9TLuoqU1qIA3YU440Q0qhcvGUHuTIJqcpDNl0NyNeIPHT8-hcfEMZl4H6OK8HskLewAO8C8VS4Rz-Ov6sJJqCk-hioRYpnqZOw9QvQQ0qnQDRA7x1fMHX0Ht0C0cM79qaDMeL7p7hh118vrs6_Z5c_v_04_3KZuaKUS9aUslOgFbRYVBp0I1yj0RlRm1KBc5hXaEoDVYGpLPK2BZ1Lqcq81ga7Rm3Y5_3c27WZsHU4LwSjvSU_pQVtAG__VmY_2D7c26IoVZV-s2EfnwZQuFsxLnby0eHufAxrtFKrujDK5MX_0aIWRtWmkgk92aOOQoyE3fNGUtidlzZ5aXdeWq0T_eHlEc_sH_MScLoHYpLmHsnehJXm9Nh_znsEZ6OrnQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1490739781</pqid></control><display><type>article</type><title>The use of US health insurance data for surveillance of rare disorders: hereditary hemorrhagic telangiectasia</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Grosse, Scott D. ; Boulet, Sheree L. ; Grant, Althea M. ; Hulihan, Mary M. ; Faughnan, Marie E.</creator><creatorcontrib>Grosse, Scott D. ; Boulet, Sheree L. ; Grant, Althea M. ; Hulihan, Mary M. ; Faughnan, Marie E.</creatorcontrib><description>Purpose:
To assess the utility of US health insurance data for surveillance of hereditary hemorrhagic telangiectasia, an autosomal-dominant blood vasculature disorder with an estimated prevalence of 1.5–2.0 per 10,000 persons worldwide.
Methods:
We used 2005–2010 MarketScan Research Databases to identify individuals with employer-sponsored health insurance and International Classification of Disease, 9th Revision, Clinical Modification codes of 448.0 present in either one inpatient claim or two outpatient claims 30 days apart to define hereditary hemorrhagic telangiectasia. We examined frequencies of International Classification of Disease, 9th Revision, Clinical Modification codes for conditions that are complications of hereditary hemorrhagic telangiectasia among individuals with hereditary hemorrhagic telangiectasia and the general population to identify combinations of codes associated with hereditary hemorrhagic telangiectasia.
Results:
Excluding observations from one state, the average prevalence of hereditary hemorrhagic telangiectasia was 0.3 per 10,000 persons. The reported prevalence rose with age from ~0.1 per 10,000 at ages <30 years to 1.0–1.1 per 10,000 at ages 70 years and above. The condition codes that were most specific to presumed hereditary hemorrhagic telangiectasia were lung arteriovenous malformations and upper gastrointestinal angiodysplasia. Combinations of those codes and codes for brain arteriovenous malformation and epistaxis were highly predictive of reporting of hereditary hemorrhagic telangiectasia, with 20–57% of enrollees with those codes also meeting the study definition for hereditary hemorrhagic telangiectasia.
Conclusion:
Hereditary hemorrhagic telangiectasia is underrecognized in US administrative data. Administrative health data can be used to identify individuals with combinations of signs that are suggestive of hereditary hemorrhagic telangiectasia. Studies are needed to test the hypothesis that referral for evaluation of individuals with administrative records suggestive of undiagnosed hereditary hemorrhagic telangiectasia could lead to diagnosis and access to life-saving treatments for both them and affected family members.
Genet Med
16
1, 33–39.</description><identifier>ISSN: 1098-3600</identifier><identifier>EISSN: 1530-0366</identifier><identifier>DOI: 10.1038/gim.2013.66</identifier><identifier>PMID: 23703685</identifier><language>eng</language><publisher>New York: Nature Publishing Group US</publisher><subject>631/208/1516 ; 692/699 ; 692/700/1538 ; Age Factors ; Biomedical and Life Sciences ; Biomedicine ; Databases, Factual ; Female ; Human Genetics ; Humans ; Insurance, Health ; Laboratory Medicine ; Male ; original-research-article ; Rare Diseases - diagnosis ; Rare Diseases - epidemiology ; Risk Factors ; Telangiectasia, Hereditary Hemorrhagic - diagnosis ; Telangiectasia, Hereditary Hemorrhagic - epidemiology ; United States</subject><ispartof>Genetics in medicine, 2014-01, Vol.16 (1), p.33-39</ispartof><rights>American College of Medical Genetics and Genomics 2014</rights><rights>American College of Medical Genetics and Genomics</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-b51f3a63ade486a6b0cb6ec709753acce28e757a84e6ec02dda6211352967efb3</citedby><cites>FETCH-LOGICAL-c451t-b51f3a63ade486a6b0cb6ec709753acce28e757a84e6ec02dda6211352967efb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23703685$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Grosse, Scott D.</creatorcontrib><creatorcontrib>Boulet, Sheree L.</creatorcontrib><creatorcontrib>Grant, Althea M.</creatorcontrib><creatorcontrib>Hulihan, Mary M.</creatorcontrib><creatorcontrib>Faughnan, Marie E.</creatorcontrib><title>The use of US health insurance data for surveillance of rare disorders: hereditary hemorrhagic telangiectasia</title><title>Genetics in medicine</title><addtitle>Genet Med</addtitle><addtitle>Genet Med</addtitle><description>Purpose:
To assess the utility of US health insurance data for surveillance of hereditary hemorrhagic telangiectasia, an autosomal-dominant blood vasculature disorder with an estimated prevalence of 1.5–2.0 per 10,000 persons worldwide.
Methods:
We used 2005–2010 MarketScan Research Databases to identify individuals with employer-sponsored health insurance and International Classification of Disease, 9th Revision, Clinical Modification codes of 448.0 present in either one inpatient claim or two outpatient claims 30 days apart to define hereditary hemorrhagic telangiectasia. We examined frequencies of International Classification of Disease, 9th Revision, Clinical Modification codes for conditions that are complications of hereditary hemorrhagic telangiectasia among individuals with hereditary hemorrhagic telangiectasia and the general population to identify combinations of codes associated with hereditary hemorrhagic telangiectasia.
Results:
Excluding observations from one state, the average prevalence of hereditary hemorrhagic telangiectasia was 0.3 per 10,000 persons. The reported prevalence rose with age from ~0.1 per 10,000 at ages <30 years to 1.0–1.1 per 10,000 at ages 70 years and above. The condition codes that were most specific to presumed hereditary hemorrhagic telangiectasia were lung arteriovenous malformations and upper gastrointestinal angiodysplasia. Combinations of those codes and codes for brain arteriovenous malformation and epistaxis were highly predictive of reporting of hereditary hemorrhagic telangiectasia, with 20–57% of enrollees with those codes also meeting the study definition for hereditary hemorrhagic telangiectasia.
Conclusion:
Hereditary hemorrhagic telangiectasia is underrecognized in US administrative data. Administrative health data can be used to identify individuals with combinations of signs that are suggestive of hereditary hemorrhagic telangiectasia. Studies are needed to test the hypothesis that referral for evaluation of individuals with administrative records suggestive of undiagnosed hereditary hemorrhagic telangiectasia could lead to diagnosis and access to life-saving treatments for both them and affected family members.
Genet Med
16
1, 33–39.</description><subject>631/208/1516</subject><subject>692/699</subject><subject>692/700/1538</subject><subject>Age Factors</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Databases, Factual</subject><subject>Female</subject><subject>Human Genetics</subject><subject>Humans</subject><subject>Insurance, Health</subject><subject>Laboratory Medicine</subject><subject>Male</subject><subject>original-research-article</subject><subject>Rare Diseases - diagnosis</subject><subject>Rare Diseases - epidemiology</subject><subject>Risk Factors</subject><subject>Telangiectasia, Hereditary Hemorrhagic - diagnosis</subject><subject>Telangiectasia, Hereditary Hemorrhagic - epidemiology</subject><subject>United States</subject><issn>1098-3600</issn><issn>1530-0366</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc9r3TAMx83YWNu3nXofPg7avNlxYic9DEbpfkBhh7VnozhK4pLErZwU-t_Xb68rHQx2ktD3IyHpy9ixFFspVPWp99M2F1JttX7FDmWpRCaU1q9TLuoqU1qIA3YU440Q0qhcvGUHuTIJqcpDNl0NyNeIPHT8-hcfEMZl4H6OK8HskLewAO8C8VS4Rz-Ov6sJJqCk-hioRYpnqZOw9QvQQ0qnQDRA7x1fMHX0Ht0C0cM79qaDMeL7p7hh118vrs6_Z5c_v_04_3KZuaKUS9aUslOgFbRYVBp0I1yj0RlRm1KBc5hXaEoDVYGpLPK2BZ1Lqcq81ga7Rm3Y5_3c27WZsHU4LwSjvSU_pQVtAG__VmY_2D7c26IoVZV-s2EfnwZQuFsxLnby0eHufAxrtFKrujDK5MX_0aIWRtWmkgk92aOOQoyE3fNGUtidlzZ5aXdeWq0T_eHlEc_sH_MScLoHYpLmHsnehJXm9Nh_znsEZ6OrnQ</recordid><startdate>20140101</startdate><enddate>20140101</enddate><creator>Grosse, Scott D.</creator><creator>Boulet, Sheree L.</creator><creator>Grant, Althea M.</creator><creator>Hulihan, Mary M.</creator><creator>Faughnan, Marie E.</creator><general>Nature Publishing Group US</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope><scope>5PM</scope></search><sort><creationdate>20140101</creationdate><title>The use of US health insurance data for surveillance of rare disorders: hereditary hemorrhagic telangiectasia</title><author>Grosse, Scott D. ; Boulet, Sheree L. ; Grant, Althea M. ; Hulihan, Mary M. ; Faughnan, Marie E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-b51f3a63ade486a6b0cb6ec709753acce28e757a84e6ec02dda6211352967efb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>631/208/1516</topic><topic>692/699</topic><topic>692/700/1538</topic><topic>Age Factors</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Databases, Factual</topic><topic>Female</topic><topic>Human Genetics</topic><topic>Humans</topic><topic>Insurance, Health</topic><topic>Laboratory Medicine</topic><topic>Male</topic><topic>original-research-article</topic><topic>Rare Diseases - diagnosis</topic><topic>Rare Diseases - epidemiology</topic><topic>Risk Factors</topic><topic>Telangiectasia, Hereditary Hemorrhagic - diagnosis</topic><topic>Telangiectasia, Hereditary Hemorrhagic - epidemiology</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Grosse, Scott D.</creatorcontrib><creatorcontrib>Boulet, Sheree L.</creatorcontrib><creatorcontrib>Grant, Althea M.</creatorcontrib><creatorcontrib>Hulihan, Mary M.</creatorcontrib><creatorcontrib>Faughnan, Marie E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Genetics in medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Grosse, Scott D.</au><au>Boulet, Sheree L.</au><au>Grant, Althea M.</au><au>Hulihan, Mary M.</au><au>Faughnan, Marie E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The use of US health insurance data for surveillance of rare disorders: hereditary hemorrhagic telangiectasia</atitle><jtitle>Genetics in medicine</jtitle><stitle>Genet Med</stitle><addtitle>Genet Med</addtitle><date>2014-01-01</date><risdate>2014</risdate><volume>16</volume><issue>1</issue><spage>33</spage><epage>39</epage><pages>33-39</pages><issn>1098-3600</issn><eissn>1530-0366</eissn><abstract>Purpose:
To assess the utility of US health insurance data for surveillance of hereditary hemorrhagic telangiectasia, an autosomal-dominant blood vasculature disorder with an estimated prevalence of 1.5–2.0 per 10,000 persons worldwide.
Methods:
We used 2005–2010 MarketScan Research Databases to identify individuals with employer-sponsored health insurance and International Classification of Disease, 9th Revision, Clinical Modification codes of 448.0 present in either one inpatient claim or two outpatient claims 30 days apart to define hereditary hemorrhagic telangiectasia. We examined frequencies of International Classification of Disease, 9th Revision, Clinical Modification codes for conditions that are complications of hereditary hemorrhagic telangiectasia among individuals with hereditary hemorrhagic telangiectasia and the general population to identify combinations of codes associated with hereditary hemorrhagic telangiectasia.
Results:
Excluding observations from one state, the average prevalence of hereditary hemorrhagic telangiectasia was 0.3 per 10,000 persons. The reported prevalence rose with age from ~0.1 per 10,000 at ages <30 years to 1.0–1.1 per 10,000 at ages 70 years and above. The condition codes that were most specific to presumed hereditary hemorrhagic telangiectasia were lung arteriovenous malformations and upper gastrointestinal angiodysplasia. Combinations of those codes and codes for brain arteriovenous malformation and epistaxis were highly predictive of reporting of hereditary hemorrhagic telangiectasia, with 20–57% of enrollees with those codes also meeting the study definition for hereditary hemorrhagic telangiectasia.
Conclusion:
Hereditary hemorrhagic telangiectasia is underrecognized in US administrative data. Administrative health data can be used to identify individuals with combinations of signs that are suggestive of hereditary hemorrhagic telangiectasia. Studies are needed to test the hypothesis that referral for evaluation of individuals with administrative records suggestive of undiagnosed hereditary hemorrhagic telangiectasia could lead to diagnosis and access to life-saving treatments for both them and affected family members.
Genet Med
16
1, 33–39.</abstract><cop>New York</cop><pub>Nature Publishing Group US</pub><pmid>23703685</pmid><doi>10.1038/gim.2013.66</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1098-3600 |
| ispartof | Genetics in medicine, 2014-01, Vol.16 (1), p.33-39 |
| issn | 1098-3600 1530-0366 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4453870 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | 631/208/1516 692/699 692/700/1538 Age Factors Biomedical and Life Sciences Biomedicine Databases, Factual Female Human Genetics Humans Insurance, Health Laboratory Medicine Male original-research-article Rare Diseases - diagnosis Rare Diseases - epidemiology Risk Factors Telangiectasia, Hereditary Hemorrhagic - diagnosis Telangiectasia, Hereditary Hemorrhagic - epidemiology United States |
| title | The use of US health insurance data for surveillance of rare disorders: hereditary hemorrhagic telangiectasia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T17%3A49%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20use%20of%20US%20health%20insurance%20data%20for%20surveillance%20of%20rare%20disorders:%20hereditary%20hemorrhagic%20telangiectasia&rft.jtitle=Genetics%20in%20medicine&rft.au=Grosse,%20Scott%20D.&rft.date=2014-01-01&rft.volume=16&rft.issue=1&rft.spage=33&rft.epage=39&rft.pages=33-39&rft.issn=1098-3600&rft.eissn=1530-0366&rft_id=info:doi/10.1038/gim.2013.66&rft_dat=%3Cproquest_pubme%3E1639473724%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1490739781&rft_id=info:pmid/23703685&rfr_iscdi=true |